BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vigabatrin (Sabril) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vigabatrin (Sabril)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04987463-7547@assetmemo.bio
DTSTAMP:20261121T010133Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Vigabatrin (Sabril): Phase 2/3 readout est. (NCT04987463)
DESCRIPTION:Vigabatrin (Sabril)\, phase 2/3.\nStudy: Efficacy and Safety of
  Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Compl
 ex Symptoms in Infants\nEstimated primary completion: December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/vigabatrin-sabril#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04987463
URL:https://assetmemo.bio/drug/vigabatrin-sabril#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
